Show simple item record

dc.contributor.authorKnill, AK
dc.contributor.authorBlackledge, MD
dc.contributor.authorCurcean, A
dc.contributor.authorLarkin, J
dc.contributor.authorTurajlic, S
dc.contributor.authorRiddell, A
dc.contributor.authorKoh, DM
dc.contributor.authorMessiou, C
dc.contributor.authorWinfield, JM
dc.coverage.spatialGermany
dc.date.accessioned2022-12-22T12:12:08Z
dc.date.available2022-12-22T12:12:08Z
dc.date.issued2022-09-28
dc.identifier10.1007/s00330-022-09088-5
dc.identifier.citationEuropean Radiology, 2022,
dc.identifier.issn0938-7994
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5616
dc.identifier.eissn1432-1084
dc.identifier.eissn1432-1084
dc.identifier.doi10.1007/s00330-022-09088-5
dc.description.abstractOBJECTIVE: To establish optimised diffusion weightings ('b-values') for acquisition of whole-body diffusion-weighted MRI (WB-DWI) for estimation of the apparent diffusion coefficient (ADC) in patients with metastatic melanoma (MM). Existing recommendations for WB-DWI have not been optimised for the tumour properties in MM; therefore, evaluation of acquisition parameters is essential before embarking on larger studies. METHODS: Retrospective clinical data and phantom experiments were used. Clinical data comprised 125 lesions from 14 examinations in 11 patients with multifocal MM, imaged before and/or after treatment with immunotherapy at a single institution. ADC estimates from these data were applied to a model to estimate the optimum b-value. A large non-diffusing phantom was used to assess eddy current-induced geometric distortion. RESULTS: Considering all tumour sites from pre- and post-treatment examinations together, metastases exhibited a large range of mean ADC values, [0.67-1.49] × 10-3 mm2/s, and the optimum high b-value (bhigh) for ADC estimation was 1100 (10th-90th percentile: 740-1790) s/mm2. At higher b-values, geometric distortion increased, and longer echo times were required, leading to reduced signal. CONCLUSIONS: Theoretical optimisation gave an optimum bhigh of 1100 (10th-90th percentile: 740-1790) s/mm2 for ADC estimation in MM, with the large range of optimum b-values reflecting the wide range of ADC values in these tumours. Geometric distortion and minimum echo time increase at higher b-values and are not included in the theoretical optimisation; bhigh in the range 750-1100 s/mm2 should be adopted to maintain acceptable image quality but performance should be evaluated for a specific scanner. KEY POINTS: • Theoretical optimisation gave an optimum high b-value of 1100 (10th-90th percentile: 740-1790) s/mm2 for ADC estimation in metastatic melanoma. • Considering geometric distortion and minimum echo time (TE), a b-value in the range 750-1100 s/mm2 is recommended. • Sites should evaluate the performance of specific scanners to assess the effect of geometric distortion and minimum TE.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofEuropean Radiology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectApparent diffusion coefficient
dc.subjectDiffusion magnetic resonance imaging
dc.subjectMelanoma
dc.subjectMetastasis
dc.subjectWhole-body imaging
dc.titleOptimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanoma.
dc.typeJournal Article
dcterms.dateAccepted2022-08-04
dc.date.updated2022-12-22T12:11:46Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1007/s00330-022-09088-5
rioxxterms.licenseref.startdate2022-09-28
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36169688
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/19/20 Starting Cohort
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1007/s00330-022-09088-5
icr.researchteamComputational Imaging
icr.researchteamRMH Honorary Faculty
icr.researchteamAppl Phys in Clinical MRI
dc.contributor.icrauthorKnill, Annemarie
dc.contributor.icrauthorBlackledge, Matthew
icr.provenanceDeposited by Mr Arek Surman on 2022-12-22. Deposit type is initial. No. of files: 1. Files: s00330-022-09088-5.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/